CREDELIO- antiparasitic for dogs - 3 tablets

For the treatment of flea and tick infestation in dogs.
The veterinary medicinal product has the activity of immediate and persistent elimination for up to a month of fleas (Ctenocephalides felis and C. canis) and ticks (Rhipicephalus sanguineus, Ixodes ricinus, I. hexagonus and Dermacentor reticulatus).
Fleas and ticks must attach to the host and begin to feed in order to be exposed to the active substance.
The veterinary medicinal product can be used as part of a therapeutic strategy in the control of allergic dermatitis caused by flea saliva.

Contraindications
Do not use in case of hypersensitivity to the active substance or to any of the excipients.

The parasites must begin to feed in order to be exposed to the lotilaner; Consequently, the risk of transmission of diseases through parasites cannot be completely ruled out.

All safety and efficacy data were obtained after administration to dogs and puppies aged at least 8 weeks and with a body weight of at least 1.3 kg. The decision to use this veterinary medicinal product in puppies under 8 weeks of age or with a body weight of less than 1.3 kg must be made on the basis of the risk / benefit assessment carried out by the responsible veterinarian.
Special precautions to be taken by the person administering the veterinary medicinal product to animals Wash hands after handling the product.
In case of accidental ingestion, seek medical advice immediately and show the package leaflet or the label to the physician.
Side effects (frequency and severity)
Very rarely, mild and transient gastrointestinal effects such as vomiting and diarrhea have been reported based on post-marketing experience. These signs usually go away without treatment.

The frequency of adverse reactions is defined using the following convention:
- Very common (more than 1 in 10 treated animals with side effects)
- Common (more than 1 but less than 10 animals out of 100 treated animals)
- Uncommon (more than 1 but less than 10 animals per 1000 animals treated)
- Rare (more than 1 but less than 10 animals out of 10 000 treated animals)
- Very rare (less than 1 in 10,000 animals treated, including isolated reports).
Use during pregnancy, lactation or lay. Laboratory studies in rats did not produce any evidence of teratogenic effects or any other adverse effects on reproductive capacity in males and females. The safety of the veterinary medicinal product has not been established in pregnant or lactating dogs or in breeding dogs. Use only in accordance with the risk / benefit assessment performed by the responsible veterinarian.
Interactions with other medicinal products or other forms of interaction
They don't know each other. During clinical trials, no interactions were observed between Credelio chewable tablets for dogs and routine veterinary medicinal products.

Lotilaner, a pure enantiomer of the isoxazoline class, is active against fleas (Ctenocephalides felis and Ctenocephalides canis), as well as against the tick species Dermacentor reticulatus, Ixodes hexagonus, Ixodes ricinus, Rhipicephalus sanguineus.
Lotilaner is a potent inhibitor of chlorine ion channels regulated by gamma-aminobutyric acid (GABA), causing the rapid death of ticks and fleas. Lotilaner activity was not affected by resistance to organochlorine compounds (eg cyclodiene, dieldrin), phenylpyrazoles (eg fipronil), neonicotinoids (eg imidacloprid), formamidines (eg amitraz) and pyrethroids (eg cypermethrin). ).
For fleas, the installation of efficacy occurs within 4 hours of fixation and lasts one month after administration of the product. Fleas existing on the animal before administration are eliminated within 6 hours.
For ticks, the installation of efficacy occurs within 48 hours of fixation and lasts one month after administration of the product. Ticks (I. ricinus) existing on the animal before administration are removed within 8 hours.
The veterinary medicinal product removes fleas that exist on animals and have recently hatched before they can lay eggs. Therefore, the product interrupts the life cycle of fleas and prevents contamination of the environment with fleas in areas where dogs have access.

After oral administration, lotilaner is absorbed immediately and the maximum plasma concentration is reached in 2 hours. Food intensifies absorption. The half-life until elimination is about 4 weeks. This long half-life until elimination ensures effective plasma concentrations over the entire dose interval.
The main route of elimination is by biliary excretion, renal excretion being the secondary route of elimination (less than 10% of the dose). Lotilaner is metabolysed to a small extent in several hydrophilic compounds that can be detected in feces and urine.